[go: up one dir, main page]

RU2006102867A - Производные 5-замещенного хиназолинона - Google Patents

Производные 5-замещенного хиназолинона Download PDF

Info

Publication number
RU2006102867A
RU2006102867A RU2006102867/04A RU2006102867A RU2006102867A RU 2006102867 A RU2006102867 A RU 2006102867A RU 2006102867/04 A RU2006102867/04 A RU 2006102867/04A RU 2006102867 A RU2006102867 A RU 2006102867A RU 2006102867 A RU2006102867 A RU 2006102867A
Authority
RU
Russia
Prior art keywords
optionally substituted
group
compound according
alkyl
aryl
Prior art date
Application number
RU2006102867/04A
Other languages
English (en)
Inventor
Элберт ЧИНЬ (US)
Элберт ЧИНЬ
Ричард Лео КУРНОЙЕР (US)
Ричард Лео КУРНОЙЕР
Пол Франсис КАЙТЦ (US)
Пол Франсис КАЙТЦ
Ын Ке ЛИ (US)
Ын Ке ЛИ
Франсиско-Хавьер ЛОПЕС-ТАПИА (US)
Франсиско-Хавьер ЛОПЕС-ТАПИА
Крис Ричард МЕЛВИЛЛ (US)
Крис Ричард МЕЛВИЛЛ
Фернандо ПАДИЛЛА (US)
Фернандо ПАДИЛЛА
Клаус Курт ВАЙНХАРДТ (US)
Клаус Курт ВАЙНХАРДТ
Original Assignee
Ф.Хоффманн-Ля Рош Аг (Ch)
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)
Publication of RU2006102867A publication Critical patent/RU2006102867A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (8)

1. Соединение формулы I
Figure 00000001
где Z означает -С(=O)- или -S(=O)2-,
R и R′ означают (низш.)алкокси,
R5 выбирают из группы, включающей галоген, циано, гидрокси, необязательно замещенный фенил, -R6 и -OR6,
R6 означает алкил, алкоксиалкил, гидроксиалкил, необязательно замещенный бензилоксиалкокси, необязательно замещенный фенокси, аминоалкил, необязательно замещенный арил, необязательно замещенный гетероарил, циклоалкил или циклоалкилокси, и
Q означает моноциклический или бициклический гетероциклический цикл, выбранный из групп (S), (Т), (U) и (V)
Figure 00000002
,
Figure 00000003
,
Figure 00000004
и
Figure 00000005
где В означает необязательно замещенный конденсированный арильный или гетероарильный цикл,
R7 присоединен к любому доступному атому углерода пиперидинильного или пиперазинильного цикла и в каждом случае является независимо выбранным из группы, включающей алкил, замещенный алкил, галоген, циано, гидрокси, алкокси, галогеналкокси, амино и алкиламино, или в другом варианте, если Q означает цикл (Т), то две группы R7, присоединенные к разным атомам углерода, вместе образуют углерод-углеродный мостик, содержащий в своем составе от одного до двух атомов углерода,
R8 означает - K-R14,
R9 и R10 (1) независимо выбирают из -L-R15, или в другом варианте, (2) R9 и R10 вместе образуют необязательно замещенный спироциклический цикл,
К и L независимо выбирают из группы, включающей химическую связь, необязательно замещенный С1-С4алкилен, -M1-O-М2-, -M1-C(=O)-M2-, -M1-С(O)2-М2-, -M1-C(=O)NR16-M2- и -M1-NR16-M2-, где M1 и M2 выбирают из группы, включающей химическую связь и необязательно замещенный С1-С4алкилен,
R14 и R15 независимо выбирают из группы, включающей водород, необязательно замещенный алкил, арил, гетероарил, циклоалкил или гетероциклил, при условии, если К или L означает химическую связь или -NR16-, то R14 и R15 не означают фенил, пиридил или пиримидинил, содержащий заместитель в пара-положении, который означает CO2R22, где R22 выбирают из группы, включающей водород, алкил, арил, арилалкил, гуанидинил, гидрокси, алкокси, арилокси и арилалкилокси,
R16 выбирают из группы, включающей водород и алкил,
m равно 0, 1, 2, 3 или 4,
n равно 0 или 1,
р равно 0, 1 или 2,
q равно 0 или 1, или
его изомер, или фармацевтически приемлемая соль, гидрат или пролекарство.
2. Соединение по п.1, выбранное из группы, включающей
2-[4-(1Н-имидазол-2-ил)пиперазин-1-ил]-5,6,7-триметокси-1Н-хиназолин-4-он,
2-[4-(2-имидазол-1-илэтил)пиперидин-1-ил]-6,7-диметокси-5-метил-1Н-хиназолин-4-он,
4-(4-фторфенил)-9-(5,6,7-триметокси-4-оксо-1,4-дигидрохиназолин-2-ил)-1-окса-4,9-диазаспиро[5.5]ундекан-3-он и
N-[2-(6,7-диметокси-5-метил-4-оксо-1,4-дигидрохиназолин-2-ил)-1,2,3,4-тетрагидроизохинолин-5-илметил]-N-метил-2-метиламиноацетамид.
3. Соединение по п.1 для применения в качестве терапевтически активного вещества.
4. Фармацевтическая композиция, включающая терапевтически эффективное количество по меньшей мере одного соединения по п.1 и по меньшей мере один фармацевтически приемлемый носитель.
5. Способ лечения патологического состояния у пациента, которое модулируется α-1A/B-адренорецептором, причем указанный способ включает введение субъекту, который нуждается в таком лечении, терапевтически эффективного количества по меньшей мере одного соединения по п.1.
6. Способ по п.5, где патологическое состояние выбирают из нарушений и симптомов заболевания мочевых путей, сексуальной дисфункции, доброкачественной гипертрофии предстательной железы и боли.
7. Применение соединения по п.1 для получения лекарственного средства, включающего соединение по п.1, предназначенного для лечения патологического состояния у пациента, которое модулируется г α-1А/В-адренорецептором.
8. Способ получения соединения по п.1.
RU2006102867/04A 2003-07-02 2004-06-29 Производные 5-замещенного хиназолинона RU2006102867A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48453603P 2003-07-02 2003-07-02
US60/484,536 2003-07-02

Publications (1)

Publication Number Publication Date
RU2006102867A true RU2006102867A (ru) 2007-08-10

Family

ID=34062053

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006102867/04A RU2006102867A (ru) 2003-07-02 2004-06-29 Производные 5-замещенного хиназолинона

Country Status (17)

Country Link
US (1) US20050124607A1 (ru)
EP (1) EP1644343B1 (ru)
JP (1) JP2009513504A (ru)
KR (1) KR100737036B1 (ru)
CN (1) CN1845908A (ru)
AR (1) AR045006A1 (ru)
AT (1) ATE366242T1 (ru)
AU (1) AU2004255585A1 (ru)
BR (1) BRPI0412163A (ru)
CA (1) CA2530450A1 (ru)
DE (1) DE602004007387T2 (ru)
ES (1) ES2290726T3 (ru)
MX (1) MXPA06000185A (ru)
PL (1) PL1644343T3 (ru)
RU (1) RU2006102867A (ru)
TW (1) TW200514782A (ru)
WO (1) WO2005005397A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
CN1884262B (zh) * 2005-06-24 2014-06-25 中国人民解放军军事医学科学院毒物药物研究所 4-氨基哌啶类化合物及其医药用途
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CN101225083A (zh) 2007-01-16 2008-07-23 北京摩力克科技有限公司 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
JP5485148B2 (ja) 2007-06-21 2014-05-07 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
CA2832822A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2864322B1 (en) 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
CN107690429B (zh) * 2015-04-07 2022-02-25 Ela制药有限公司 用于治疗和/或预防细胞或组织坏死的组合物，其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶
US10196383B2 (en) * 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
JP6964343B2 (ja) 2015-11-20 2021-11-10 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
WO2017164707A1 (ko) * 2016-03-24 2017-09-28 주식회사 케미메디 전립선 비대증에서 기인한 방광출구폐색에 의해 2차적인 방광 변성으로 유발된 과민성 방광의 예방 또는 치료용 의약 조성물 및 건강기능식품
ES2998084T3 (en) 2017-12-27 2025-02-19 Japanese Found For Cancer Res Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
CN113754594B (zh) * 2021-09-16 2025-01-21 中国药科大学 喹唑啉酮类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084457A (en) * 1990-07-23 1992-01-28 American Cyanamid Company Benzoylaminoquinazolinones
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
ES2241891T3 (es) * 2001-01-02 2005-11-01 F. Hoffmann-La Roche Ag Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b.
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
DE602004007387D1 (de) 2007-08-16
EP1644343A1 (en) 2006-04-12
JP2009513504A (ja) 2009-04-02
US20050124607A1 (en) 2005-06-09
AR045006A1 (es) 2005-10-12
CN1845908A (zh) 2006-10-11
DE602004007387T2 (de) 2008-03-06
BRPI0412163A (pt) 2006-08-22
CA2530450A1 (en) 2005-01-20
KR100737036B1 (ko) 2007-07-09
PL1644343T3 (pl) 2007-12-31
TW200514782A (en) 2005-05-01
KR20060027824A (ko) 2006-03-28
ATE366242T1 (de) 2007-07-15
AU2004255585A1 (en) 2005-01-20
ES2290726T3 (es) 2008-02-16
MXPA06000185A (es) 2006-04-11
EP1644343B1 (en) 2007-07-04
WO2005005397A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
US11524955B2 (en) 2,4-diamino-pyrimidine compounds and method for making and using the compounds
US10774065B2 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
RU2006102867A (ru) Производные 5-замещенного хиназолинона
AU2014315457B2 (en) Compounds useful as immunomodulators
ES2782376T3 (es) Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades
TWI579284B (zh) 咪唑并吡咯啶酮化合物
AU2020378407B2 (en) Heterocyclic RIP1 inhibitory compounds
ES2299888T3 (es) Pirid (2,3-d)pirimidin-2,4-diaminas como inhibidores de pde 2.
JP5662321B2 (ja) 骨髄腫の治療のための置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンの使用
CN112867721A (zh) Sting激动性化合物
TW201819386A (zh) Shp2磷酸酶抑制劑及其使用方法
EA010393B1 (ru) Производные хинолинона
EP3331879A1 (en) Benzazole compounds and methods for making and using the compounds
WO2024091409A1 (en) Tricyclic derivatives as kras inhibitors
JP2020507566A (ja) ベンゾチオフェンエストロゲン受容体モジュレーター
US20250186391A1 (en) Oral complement factor d inhibitors
EP2716302A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
BRPI0613491A2 (pt) antagonistas de piperazina-piperidina e agonistas do receptor de 5-ht1a
JP2019069990A (ja) 癌を処置するためのセファロスポリンの新規誘導体
RU2006138606A (ru) Ингибиторы киназы
JP2003516994A5 (ru)
RU2007125659A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
CN102796121B (zh) 3-芳基-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类衍生物及其应用
JP2712222B2 (ja) 抗不安薬

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20081111